This study aligns with established trends in NSCLC demographics, highlighting male predilection and the challenge of diagnosing advanced-stage disease. Patients harboring EGFR mutations were treated with tyrosine kinase inhibitors (TKIs), such as osimertinib or erlotinib, while those with ALK rearrangements received ALK inhibitors, such as alectinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.